TransCon CNP

Designed for continuous CNP exposure to rebalance bone growth in skeletal disorders

Designed for continuous CNP exposure to rebalance bone growth in skeletal disorders

Vector-Smart-Object-copy

TransCon technology has extended exposure of CNP from 2.5 minutes to 120 hours - unlocking its therapeutic potential to pursue a new frontier of growth biology.

Explore

You are about to access www.ascendispharma.us, which includes information intended for U.S. residents only. Click below to confirm.

Are you a U.S. resident?

If so, please confirm below to proceed to our U.S. website. If not, continue to our global website.